Your browser doesn't support javascript.
loading
Switching the Smoothened Inhibitor May Have Benefit in Advanced Basal Cell Carcinoma.
Khalid, Bilal; Mukherjee, Sarbajit; Ibrahimi, Sami; Cannon, Trinitia; Gilles, Elizabeth; Moreau, Annie; Razaq, Mohammad.
Affiliation
  • Khalid B; Department of Medicine, Hematology-Oncology Section, The University of Oklahoma Health Sciences Center, Oklahoma City, OK.
  • Mukherjee S; Department of Medicine, Hematology-Oncology Section, The University of Oklahoma Health Sciences Center, Oklahoma City, OK.
  • Ibrahimi S; Department of Medicine, Hematology-Oncology Section, The University of Oklahoma Health Sciences Center, Oklahoma City, OK.
  • Cannon T; Departments of Otorhinolaryngology and.
  • Gilles E; Pathology, The University of Oklahoma Health Sciences Center, Oklahoma City, OK.
  • Moreau A; Department of Ophthalmology, The University of Oklahoma Health Sciences Center, Dean McGee Eye Institute, Oklahoma City, OK.
  • Razaq M; Department of Medicine, Hematology-Oncology Section, The University of Oklahoma Health Sciences Center, Oklahoma City, OK.
Am J Ther ; 25(3): e394-e396, 2018.
Article in En | MEDLINE | ID: mdl-29557803
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pyridines / Skin Neoplasms / Biphenyl Compounds / Carcinoma, Basal Cell / Smoothened Receptor / Anilides / Antineoplastic Agents Limits: Humans / Male / Middle aged Language: En Journal: Am J Ther Journal subject: TERAPEUTICA Year: 2018 Document type: Article
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pyridines / Skin Neoplasms / Biphenyl Compounds / Carcinoma, Basal Cell / Smoothened Receptor / Anilides / Antineoplastic Agents Limits: Humans / Male / Middle aged Language: En Journal: Am J Ther Journal subject: TERAPEUTICA Year: 2018 Document type: Article